课题基金 / 基金详情

项目摘要

项目成果

Bruce S Bochner的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 位于西北大学范伯格医学院的行政核心A的目标 在Bruce Bochner博士的领导和监督下,将为 董事和执行委员会,并负责财务管理和 通讯。除了管理预算和满足NIH的报告要求外,Core A还将采取 负责项目间和项目内部的沟通(主要是基于网络),组织项目 会议(包括执行委员会会议、外部咨询委员会会议和小岛屿发展中国家 参与年度调查员会议),协助旅行计划和报销 协调与NIAID和行政中心的沟通。全面领导 该计划将通过一个由项目负责人(Bochner, 保尔森和施纳尔)。执行委员会将至少每季度举行一次会议,面对面或通过网络举行。 会议,评估每个项目的具体生产力,利用协作机会,并 在遇到进展障碍时提供见解和建议。除执行委员会外, 将征求外部咨询委员会的意见,该委员会将在此之后(如果)每年召开一次会议 AADCRC的提案得到了资助。
英文摘要
ABSTRACT The goals of the Administrative Core A, located at the Northwestern University Feinberg School of Medicine under the leadership and supervision of Dr. Bruce Bochner, are to provide efficient administrative support to the director and the Executive Committee and to take responsibility for financial management and communications. In addition to managing budgets and fulfilling NIH reporting requirements, Core A will take responsibility for inter-Program and intra-Program communications (primarily web-based), organize Program meetings (including Executive Committee meetings, External Advisory Board meetings, and SALTAD involvement in the annual Investigator's meeting), assist in travel planning and reimbursement for participants, and coordinate communications with NIAID and the Administrative Center. Overall leadership of the Program will be accomplished with an Executive Committee consisting of the project leaders (Bochner, Paulson, and Schnaar). The Executive Committee will meet at least quarterly, either in person or by web conference, to assess the specific productivity of each project, leverage opportunities for collaboration, and to provide insights and advice if obstacles to progress are encountered. In addition to the Executive Committee, advice will be sought from an External Advisory Committee that will be convened annually after (if) this AADCRC proposal is funded.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Exploiting Siglec-6 for targeted anti-allergy drug delivery into human mast cells
Exploiting Siglec-6 for targeted anti-allergy drug delivery into human mast cells
Using siglecs and their ligands to treat allergic diseases SALTAD
Defining Siglec-6 and Siglec-8 function on effector cells of allergic diseases
海外基金